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CURE OF MURINE LEISHMANIASIS WITH
ANTI-INTERLEUKIN 4 MONOCLONAL ANTIBODY
Evidence for a T Cell-dependent, Interferon -y-independent Mechanism
BY MICHAEL D. SADICK, FREDERICK P HEINZEL, BETTIE J. HOLADAY,
ROBERT T. PU, ROGELIO S. DAWKINS, AND RICHARD M. LOCKSLEY
From the Division of Infectious Diseases, University of California San Francisco Medical Center,
Department of Medicine, San Francisco, California 94143
Infection of inbred mouse strains with Leishmania major causes local infection with
subsequent resolution and establishment of immunity in genetically resistant mice,
but progressive, disseminated fatal disease in genetically susceptible mice. Healing
in resistant strains, such as C57BL/6, is associated with the capacity oflymphocytes
to generate IFN-y in response to Leishmania antigens in vitro (1) and the appearance
of IFN-y mRNA in lymphoid tissues in vivo (2). IFN-y has been identified as the
major macrophage-activating factor produced by stimulated T cells (3-5), and is
capable of activating macrophages to kill the obligate intracellular amastigote form
of the parasite (6-8).
Susceptible BALB/c mice can be immunologically manipulated before infection,
e.g ., by sublethal irradiation (9) or transient depletion of CD4+ T cells with the anti-
CD4 mAbGK1.5 (GK1 .5-BALB/c; 1, 10), such that these animals contain infection
and establish protective immunity against reinfection . The control of infection in
these mice has also been correlated with production of IFN-y by T cells in vivo and
in vitro (1, 2) . Untreated BALB/c mice, however, do not generate significant IFN-y,
despite the demonstrable expansion of the CD4+ T cell population during progres-
sive infection (2, 11). In contrast to the healing mice, these animals have mRNA
for IL-4 in lymphoid tissues in vivo together with elevated levels of serum IgE (2) .
These data suggest that healing or fatally infected BALB/c mice expand distinct
CD4+ T cell subsets that correlate with control or progression of disease . These in
vivo cells would be correlates of the Thl andTh2 cells previously distinguished and
defined at the clonal level in vitro (12, 13).
Based on these observations, we administered an IL-4-specific neutralizing mAb
in order to interfere with expansion and function ofTh2 cell populations in infected
BALB/c mice . In preliminary experiments, such therapy clearly attenuated the course
ofearly disease (2). In experiments reported here, anti-IL-4 therapy initiated at the
time ofinfection attenuated disease in 100% of susceptible BALB/c mice and resulted
in complete resolution ofdisease in 85% ofmice with the establishment ofprotective
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immunity. Further, cure was independent ofIFN-y, asjudged by the failure ofcoad-
ministration ofneutralizing anti-IFN-y mAbto alter the outcome of anti-IL-4 therapy.
This was in contrast to resistant C57BL/6 or GK1.5-BALB/c mice, both of which
developed progressive infection when treated with anti-IFN-y mAb.
Materials and Methods
Mice. Female BALB/c and C57BL/6 mice, 6-8 wk old, were purchased from The Jackson
Laboratory, Bar Harbor, ME. Female athymic nude BALB/c (nu/nu) mice, 6-8 wk old, were
purchased from Harlan Sprague Dawley, Inc., Indianapolis, IN, and housed in the specific
pathogen-free animal care facility at U.C .S .F. Medical Center.
Parasites. L. major (World Health Organization strain WHOM/IR/-/173) was cultured as
promastigotes in M199 (Cell Culture Facility, U.C .S.F. Medica l Center) containing 3017o FCS
(Gemini Bio-Products, Calabasas, CA) as described (14, 15) . Metacyclic stage promastigotes
were harvested from stationary phase cultures by centrifugation and washed in HBSS (Cell
Culture Facility, U.C.S.F. Medical Center) before use.
mAbs. mAbs included GK1.5 (rat IgG2b), which recognizes the murine CD4 antigen (16),
53-6 .72 (rat IgG2a), which recognizes the murine CD8antigen (17), R4 6A2 (rat IgGl), which
neutralizes murine IFN-'y (18), and 11B11 (rat IgGI), which neutralizes murine IL-4 (19) .
mAbs were prepared from rat/mouse heterohybridomas grown as ascites in pristane-primed
BALB/c nu/nu mice. Preparations were precipated in 45% ammonium sulfate, dialyzed against
PBS, pH 7.2, and quantitated for protein before use (20) .
IFN-y. Purified murine rIFN-y (lot no. 2271-54-F1 ; sp act, 5 x 106 antiviral U/mg; en-
dotoxin, 0.032 E.U./mg), provided as a 1 mg/ml solution in sterile buffered saline (Genen-
tech, Inc., South San Francisco, CA), was diluted to 100 kg/ml in sterile normal saline, ali-
quoted, and stored at VC before use. Beginning with the day of infection, designated BALB/c
mice received 20 hg rIFN-y intraperitoneally every other day for 6 wk .
Infection of Mice with mAbs. Selected BALB/c mice were injected intraperitoneally with
1.0 mg purified GK1 .5 in 250 p,l PBS 24 h before infection, as described (1, 10). Beginning
on the day of infection, designated mice received 0.5 mg purified 11BIl or R4 6A2, or both,
intraperitoneally once per week for 6 wk .
Infection ofMice. Mice were infected in the hind footpads with 4 x 10 6 metacyclic stage
L. major promastigotes, as described (1, 21). Footpad swelling was determined weekly using
a metric caliper. At the times designated, sera were collected and the animals were killed .
The tissue from the dorsal portion of the footpads was removed intact and frozen in OCT
compound (Miles Laboratories Inc., Naperville, IL). After thin sectioning on a cryostat (In-
ternational Equipment Co ., Needham Heights, MA), the largest transverse diameter was
prepared for histologic examination after staining with modified Wright/Geimsa (Dif Quik ;
American Scientific Products, McGawPark, IL). The spleens and draining (popliteal) lymph
nodes were used for the isolation of mRNA (see below) .
Adoptive Transfer of Cellular Immunity. Spleen and popliteal lymph node cells were isolated
from anti-IL-4-healed L. major-infected BALB/c mice at 12-15 wk after infection. The cells
were pooled and divided into three aliquots . Twowere depleted of CD4* cells or CD8* cells
by incubation with 10 14g/ml anti-CD4 mAb or 10 pg/ml anti-CD8 mAb, respectively, fol-
lowed by incubation with 1 :10 diluted complement (Rabbit LowTox M; Accurate Chemical
& Scientific Corp ., Westbury, NY). Two cycles of depletion were performed with the respec-
tive antibodies . Depletion was confirmed by flow cytometry. The third group ofcells received
no treatment. Groups of five recipient BALB/c mice were irradiated with 200 rad (22) before
intravenous administration of 10' cells from one of the three cell preparations . Control
BALB/c mice were similarly irradiated but received 10' naive BALB/c spleen cells. Addi-
tional groups included untreated mice and irradiated mice that did not receive any cell transfer.
All mice were infected 24 h after cell transfer. Disease progression was assessed by footpad
swelling and ulceration .
Northern Blot Analyses. Harvested tissues were homogenized in 6 M guanidine hydrochlo-
ride and isolated by the method of Chirgwin et al . (23). Poly(A)* RNA was subsequently
purified usingoligo-dT affinity chromatography (24), subjected to electrophoresis in 67o form-
aldehyde/1 % agarose gel (25), and transferred to nylon membranes by capillary blotting (Amer-
sham Corp., Arlington Heights, IL) (26) . The membranes were exposed to short-wave UV
light for 30 s to fix the RNA to the nylon matrix, and treated at 42°C for 4 h with prehybridiza-
tion solution containing 10% dextran before incubation with 12 P-labeled nucleic acid probe.
The probes used were IL-4 cDNA subcloned into pSP65 (2), and the 550-bp Eco RI/Eco
RV fragment of murine IFN-y (Dr. P W. Gray, Genentech, Inc .) subcloned into PSP72
(Promega Biotec, Madison, WI) . IFN-y and IL-4 antisense probes were generated using
12P-CTP (800 Ci/mmole ; New England Nuclear, Boston, MA) and SP6 RNA polymerase
(Promega Biotec) as described (2) . Membranes were hybridized with antisense RNA probes
at 65°C overnight, and washed in 0.1% SDS, 0 .1 x SSC (0.015 M NaCl, 0.0015 M sodium
citrate buffer, pH 7.0) at 65°C . Membranes were hybridized with nick-translated cDNA probe
at 42°C overnight and washed in 0.1% SDS, 0 .1 x SSC at 55°C . Washed membranes were
exposed to X-ray film as previously described (2) .
Serum IgE Determinations.
	
Sera isolated before death were quantitated for IgE using a sand-
wich ELISA with monoclonal anti-e (EM-95) as the primary antibody and biotinylated poly-
clonal rabbit-anti-4E as the secondary antibody, as described (27) .
Results
Effect ofExogenous rIFN-y in Infected BALBIc Mice. The low levels of IFN-'y pro-
duced during progressive L . major infection in susceptible BALB/c mice, in contrast
to the readily detectable levels produced by resistant C57BL/6 mice (1, 2), suggested
that parenterally administered rIFN-y might favorably influence the outcome of in-
fection in the BALB/c mice . Based on preliminary experiments, a dose of IFN-y
that was twofold below that resulting in toxicity to infected mice was used . This dose,
20 ug every 48 h, was twice that used to cure otherwise fatal murine Toxoplasma gondii
(28, 29) or Trypanosoma cruzi (30) infection . Infected BALB/c mice receiving rIFN-y
demonstrated a slight delay in footpad swelling (Fig. 1), but ulceration and histo-
logic evidence of extensive parasitization occurred in all animals (Fig. 2 C) . At 5
wk post-infection, however, treated mice had significant diminution in serum IgE
levels compared with control-infected mice (Fig . 3), indicating in vivo efficacy of
the exogenous IFN-'Y (27).
Effect of In Vivo Neutralization ofIL-4 on the Course of Leishmaniasis in BALBIc Mice.
BALB/c mice that received six weekly injections of anti-IL-4 mAb (11B11) exhibited
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FIGURE 1 . Effect ofrIFN-y or
anti-IL-4 treatment on the
progression ofL. major infection
in BALB/c mice . Footpad mea-
surements represent the mean
t SEM from 48 mice after no
treatment (O) or anti-IL-4 treat-
ment (" ), and themean t SEM
from five mice after rIFN-y
treatment (A) .
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FIGURE 2. Effect of rIFN-y or
anti-IL-4 treatment on the pro-
gression ofL. major infection in
BALB/c mice . Tissue sections
were prepared from the footpads
of 8-wk-infected untreated (A),
anti-IL-4-treated (B),.'and rIFN-
,y- treated (C) BALB/c mice and
represent the largest transverse
diameter from the dorsal sur-
face of the infected footpads
(x 750) .
significant attenuation ofdisease as compared with matched untreated animals (Fig .
1) . Footpad swelling was markedly decreased and began to resolve after 6 wk, whereas
footpads ofthe control animals progressed to ulceration and necrosis . Although dis-
ease did progress, albeit more slowly, in some of the treated mice, 85% were com-
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pletely healed by 8wk. These data represent the compiled results from 48 mice treated
with anti-IL-4. Histologic analyses of the footpads from the treated BALB/c mice
confirmed that the resolution of swelling was associated with the disappearance of
parasites (Fig . 2, A and B) . In additional experiments, the coadministration of rIFN-,y
(20 lzg every 48 h) with anti-IL-4 therapy did not augment the beneficial effect achieved
by anti-IL-4 alone (data not shown). Serum IgE levels were suppressed by >90%
in anti-IL-4-treated mice, as compared with control-infected BALB/c mice (Fig . 3) .
In contrast, BALB/c mice that received weekly injections of either nonimmune rat
sera or isotype-matched R4 6A2 anti-IFN--y (rat IgGI) developed disease andelevated
serum IgE levels indistinguishable from those in untreated infected BALB/c mice
(data not shown) .
Anti-IL-4 Effect Is Dependent on TCells. When healed, anti-IL-4-treated BALB/c
mice were rechallenged with viable promastigotes, they remained immune to rein-
fection (data not shown) . Pooled spleen andlymph node cells from anti-IL-4-treated
BALB/c mice that had resolved the primary infection were transferred into irradi-
ated BALB/c recipients before challenge with L. major promastigotes. These mice,
but not mice receiving naive BALB/c spleen cells, displayed substantial protection
against the parasite, as assessed both by footpad swelling and ulceration (Fig . 4) .
FIGURE 4. Adoptive transfer ofanti-IL-
4-induced immunity . Footpad measure-
ments from untreated L . major-infected
BALB/c mice (A) and L . major-infected
200-rad irradiated BALB/c mice that had
been injected with 107 naive BALB/c
spleen cells (A), 107 pooled lymphoid
cells from anti-IL-4-healed BALB/c (0),
107 C134-depleted pooled lymphoid cells
from anti-IL-4-healed BALB/c (O), or
107 CD8-depleted pooled lymphoid cells
fromanti-IL-4-healed BALB/c (") . Values
represent the mean t SEM from five
,---~ mice. Percentage of footpads ulcerated at
6 7 6 wk is indicated.
FIGURE 3. Effect ofanti-IL-4,
rIFN-.y, or anti-IFN-,y on the
production of serum IgE after
L . major infection . Values rep-
resent the mean t SEM from
five mice .
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Prior irradiation at these doses (in contrast to higher doses [9]) had no effect on
the subsequent course of leishmaniasis as compared with nonirradiated controls .
Treatment of the pooled cells with either anti-CD4 or anti-CD8 plus complement
significantly abrogated the capacity of the transferred cells to prevent footpad swelling
and completely reversed the prevention of ulceration . To establish further the re-
quirement forT cells in the efficacy of anti-IL-4, athymic BALB/c nu/nu mice, which
are unable to control leishmaniasis in the absence of Tcell reconstitution (31), were
infected with L. major. Such mice showed no alteration of disease progression in re-
sponse to weekly anti-IL-4 injections (Fig. 5) . Although footpad swelling was delayed
in nude mice as compared with normal infected BALB/c mice, as previously reported
(31), histologic analysis of the infected footpads and lymphnodes at week 6 revealed
extensive parasitization of macrophages from both control and anti-IL-4-treated nude
mice (data not shown) .
Effect ofAnti-IL-4 on IFN-yandIL-4 mRNA. Prior studies have documented the
correlation between the presence of IFN-y mRNA and the capacity to heal L. major
infection (1, 2) . To assess the possible role of IFN-y in the therapeutic response of
anti-IL-4-treated mice, mRNA extracted from the spleens and lymph nodes of in-
fected mice was examined for IFN-y-specific transcripts . Although Northern blot
analysis of splenic IFN-y mRNA from the anti-IL-4-healed BALB/c mice revealed
no differences as compared with untreated mice (Fig . 6, lanes A and B), message
levels in the draining lymph nodes were approximately fourfold enhanced (Fig . 6,
lanes C and D) . Analysis of IL-4 mRNA in the same tissues similarly revealed no
change in splenic message levels accompanying anti-IL-4 treatment, but a reciprocal
fourfold decrease in specific mRNA in lymph node mRNA.
IFN-y Does not Mediate Healing Induced by Anti-IL-4. To investigate further the
mechanism of healing, in vivo neutralization of IFN-y with anti-IFN-y mAb, R4
6A2, was used to assess the role ofthis cytokine in anti-IL-4-treated BALB/c, C57BL/6,
and GK1.5-BALB/c mice .
L. major-infected BALB/c mice receiving both anti-IL-4 and anti-IFN-1' antibodies
contained the infection, as well as those receiving anti-IL-4 alone (Fig. 7 A) . In marked
contrast, infected C57BL/6 mice receiving anti-IFN-y demonstrated progressive
swelling of the footpads with ulceration by week 5 (Fig . 7 B) . A correlation between
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FIGURE 6. Effect of anti-IL-4 treatment on cytokine mRNA
production during leishmaniasis. Poly(A)' RNA (10 pg) was iso-
lated from the spleens of untreated or anti-IL-4-treated BALB/c
mice (lanes A and B, respectively) or the popliteal lymph nodes
of untreated or anti-IL-4-treated BALB/c mice (lanes C and D,
respectively) 6 wk after infection with L. major. Northern hybrid-
izations were performed using IL-4- and IFN-,y-specific probes .
FIGURE 7. Effect ofanti-IFN-'y on the pro-
gression ofL . major infection. (A) Untreated
BALB/c mice (O); anti-IL-4-treated (A); and
anti-IL-4 + anti-IFN--y-treated (A) BALB/c
mice. Footpad measurements represent the
mean t SEM from five mice. (B) Untreated
BALB/c mice (O); C57BL/6 untreated (A);
and anti-IFN-'y-treated (A) mice . Footpad
measurements represent the mean t SEM
from four mice . (C) Untreated BALB/c mice
(O); GK1.5-BALB/c untreated (A); and anti-
0 1 2 3 4 5 6 7 s v ments represent the mean t SEMfrom four
Weeks Post-infection mice .
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footpad swelling and the presence of numerous parasites was confirmed by histo-
logic examination ofthe footpads in which amastigote-parasitized macrophages were
readily detectable (Fig . 8 B). Untreated C57BL/6 mice responded to infection with
footpad swelling through the first 5-6 wk, followed by resolution without ulceration
(Fig . 7 B) . Resolution ofdisease wasconfirmed by histologic examination (Fig. 8 A) .
Similar results were seen when GK1.5-BALB/c mice were treated with anti-IFN--y .
Neutralization of IFN-y resulted in progressive infection as assessed both by size
of the local lesions and increasing numbers of amastigote-infected macrophages in
the footpads (Figs. 7 Cand 8, Cand D, respectively). In both C57BL/6 and GK1.5-
BALB/c mice, neutralization of IFN-y resulted in significant increases in serumIgE
levels as compared with untreated infected mice (Fig . 3) .
Discussion
These studies demonstrate the profound effect of neutralization of IL-4 on the
course ofotherwise fatal infection by L. major in susceptible BALB/c mice . All treated
mice had attenuated disease, and 85% were cured. The efficacy of anti-IL-4 treat-
ment required the presence of T cells, and anti-IL-4-induced protection could be
adoptively transferred in a manner dependent on both CD4+ and CD8+ cells . Sur-
prisingly, there was no evidence that cure was mediated by the generation of IFN-'r,
despite the demonstration that this cytokine was critical for healing in C57BL/6 or
GK1.5-BALB/c mice. Further, treatment with rIFN-y alone was insufficient to affect
the course of disease in infected BALB/c mice, a finding consistent with at least two
mechanisms for establishing control of leishmaniasis.
The effect ofanti-IL-4 therapy was established by measurement of footpad thick-
ness, histologic examinations demonstrating absence of parasites, and resistance of
mice to rechallenge with promastigotes 12 wk subsequent to the initial infection .
Neither control rat sera nor an isotype-matched mAb had any effect on the course
of disease, suggesting that neutralization ofIL-4 is required for activity. The finding
that anti-IL-4 therapy abrogated the rise in serum IgE seen in untreated, infected
BALB/c mice further documents the neutralization of IL-4 in vivo (32-34) . Treat-
ment of infected nu/nu BALB/c mice with anti-IL-4 had no effect on the course of
disease, indicating that T cells are required . The latter experiment further excluded
the possibility of direct antileishmanial activity by the anti-IL-4 mAb.
Because IL-4 has been proposed as a requisite growth factor for Th2 cells (13,
35), our initial assumption was that anti-IL-4 therapy was effective due to a selective
blockade of the expansion of Leishmania antigen-specific Th2 cells . The decrease in
IL-4 mRNA and reciprocal increase in IFN-y mRNA that occurred in the lymph
node cells draining the lesion were consistent with a proportionately greater expan-
sion ofThl cells in response to inhibition ofTh2 cell division by anti-IL-4. However,
several observations suggest that this may not be the only mechanism. rIFN-y has
also been shown to effectively blockTh2 cell proliferation in vitro (36), but despite
administration of rIFN-y at doses shown to effectively ameliorate fatal infection by
T. gondii (29, 30) or by T. cruzi (31), mice infected with L. majordeveloped progressive
infection. Suppression ofserum IgE, comparable with that seen in anti-IL-4-treated
mice, demonstrated that the administered rIFN-y induced systemic effects up to
5 wk after infection. As macrophages are the only host cell parasitized by Leishmania,
neutralization of the capacity of IL-4 to deactivate macrophages, even in the pres-
SADICK ET AL .
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ence of IFN--y (37, 38), may be an important mechanism underlying the efficacy
of anti-IL-4 therapy.
Prior studies ofhealer C57BL/6 or GK1.5-BALB/cmice established acorrelation
between production of IFN-y in response to Leishmania antigen stimulation in vitro
(1) and the presence of IFN-y mRNA in lymph node and spleen cells in vivo (2)
with resolution of infection. The identification of IFN-y as a major macrophage-
activating factor andthe requirement for macrophage activation to kill this intracel-
lular parasite have been well established (5, 7, 30, 39). The studies reported here
demonstrate that IFN-y is required for healing in these mice, since the administra-
tion ofneutralizing anti-IFN-y antibody resulted in progressive, uncontrolled infec-
tion both in C57BL/6- and anti-CD4-pretreated BALB/c mice. Similar findings have
been reported recently in studies ofL. major infection in C3H/HeN mice (40). De-
spite the requirement for IFN-y in resolution of disease in these mice, rIFN-y did
not protect BALB/c mice by itself. It did not enhance the therapeutic effects of anti-
IL-4 either, suggesting that while important to the outcome of disease, IFN-y is not
sufficient by itself for the resolution of leishmaniasis in BALB/c mice.
Importantly, cure mediated by neutralization of IL-4 appeared independent of
IFN-y, since cotreatment of these mice with neutralizing anti-IFN-y mAb did not
abrogate the therapeutic effect ofthe anti-IL-4. Treatment with anti-IL-4 established
protective cellular immunity, as assessed by cell transfer experiments, that resided
in both the CD4+ and CD8+ populations. Although CD4 depletion was slightly
more effective than CD8 depletion in reversing the attenuation of footpad swelling,
the CD8 requirement supports recent observations establishing a protective role for
these cells in leishmaniasis (41, 42). The possibility that macrophage-activating factors
other than IFN-y (43, 44) or contact-mediated macrophage activation (45, 46) are
involved in the mechanism underlying the potent effects ofanti-IL-4 therapy of leish-
maniasis remains to be established . The elucidation ofthe mechanisms involved should
uncover novel redundant systems for the control of intracellular pathogens.
Summary
BALB/c mice infected with Leishmania major develop fatal, progressive disease, de-
spite an immune response characterized by expansion of CD4+ T cells in the
draining lymph nodes. The immune response has been further characterized by a
lack ofIFN-y mRNA, but increased IL-4 mRNA in lymphoid tissues, and striking
elevation of serum IgE. Treatment of infected BALB/c mice with rIFN-y at doses
shown to be beneficial in other protozoan infections was insufficient to ameliorate
L. major infection. In contrast, neutralization ofIL-4 by six weekly injections ofmAb
111311 led to attenuation of disease in 100% of animals, and complete cure in 85%.
Resolution ofdisease required the presence ofT cells, and recovered mice remained
resistant to reinfection at 12 wk . This immunity was adoptively transferable and
was dependent on both CD4' and CD8+ cells. Although administration of anti-IL-4
was associated with fourfold increase in IFN-ymRNA in lymph node cells draining
the lesion, the coadministration of neutralizing R4 6A2 anti-IFN-y mAb had no
effect on resistance to disease. This was in marked contrast to resolution of disease
in both resistant C57BL/6- and GK1.5-pretreated BALB/c mice that was abrogated
by in vivo treatment with anti-IFN-y . These data suggest anovel mechanism of cel-
lular immunity established by interference with the development of Th2 cells during
infection .
We thank Dr. Tim Mosmann (DNAX Research Institute, Palo Alto, CA) for the generous
gift ofthe 11BIl hybridoma, Dr. Robert Coffman (DNAX Research Institute) for performing
the serum-IgE analyses, and Dr. Christine Czarniecki (Genentech, Inc ., South San Fran-
cisco, CA) for the gift of murine rIFN--y .
Receivedfor publication 31 July 1989 and in revisedform 2 October 1989.
SADICK ET AL .
	
125
References
1 . Sadick, M. D., F. P. Heinzel, V. M. Shigekane, W L. Fisher, and R. M. Locksley. 1987 .
Cellular and humoral immunity to Leishmania major in genetically susceptible mice after
in vivo depletion of L3T4' T cells . J Immunol. 139:1303 .
2 . Heinzel, F. P., M. D. Sadick, B. J . Holaday, R . L . Coffman, and R. M. Locksley. 1989 .
Reciprocal expression of interferon y or interleukin 4 during the resolution or progres-
sion of murine leishmaniasis . Evidence for expansion of distinct helper T cell subsets .
J. Exp. Med. 169:59 .
3 . Svedersky, L. P, C . V. Benton, W. H . Berger, E. Rinderknecht, R . N . Harkins, and
M. A . Palladino . 1984. Biological and antigenic similarities of murine interferon y and
macrophage-activating factor. J. Exp. Med. 159:812 .
4 . Schreiber, R. D., J . L . Pace, S . W. Russell, A . Altman, and D. H . Katz . 1983 . Macro-
phage activating factor produced by a T cell hybridoma : physicochemical and biosyn-
thetic resemblance to -y-interferon . J Immunol. 131 :826 .
5 . Nathan, C . F, H. W. Murray, M. E . Wiebe, and B . Y. Rubin . 1983 . Identification of
interferon--y as the lymphokine that activates human macrophage oxidative metabolism
and antimicrobial activity. J Exp. Med. 158:670 .
6 . Titus, R . G., A . Kelso, and J . A . Louis . 1984. Intracellular destruction of Leishmania
tropica by macrophages activated with macrophage activating factor/interferon . Clin. Exp.
Immunol. 55:157 .
7 . Murray, H. W, B . Y. Rubin, and C . D. Rothermel . 1983 . Killing of intracellular Leish-
mania donovani by lymphokine-stimulated human mononuclear phagocytes . Evidence that
interferon-gamma is the activating lymphokine. J. Clin. Invest . 72:1506 .
8 . Murray, H. W., J . J . Stern, K . Welte, B . Y Rubin, S . M. Carriero, and C. F. Nathan.
1987 . Experimenta l visceral leishmaniasis : production of interleukin 2 and interferon-
gamma, tissue immune reaction, and response to treatment with interleukin 2 and inter-
feron gamma. J. Immunol. 138:2290 .
9 . Howard, J ., C . Hale, and F Liew. 1981 . Immunological regulation of experimental cuta-
neous leishmaniasis . IV. Prophylactic effect ofsublethal irradiation as a result of abroga-
tion of suppressor T cell generation in mice genetically susceptible to Leishmania tropica .
J Exp. Med. 153:557 .
10 . Titus, R . G ., R . Ceredig, J.-C . Cerottini, and J . A . Louis. 1985 . Therapeutic effect of
anti-L3T4 monoclonal antibody GK1 .5 on cutaneous leishmaniasis in genetically sus-
ceptible BALB/c mice . J. Immunol. 135:2108 .
11 . Heinzel, F P, M. D. Sadick, and R. M. Locksley. 1988 . Leishmania major : Analysis
ofcellularphenotypes in cutaneous lesions and draining lymph nodes . Exp. Parasitol. 65:258 .
12 . Mosmann, T. R., H. Cherwinski, M. W Bond, M. A. Giedlin, and R. L . Coffman .
1986. Two types of murine helper T cell clone. I . Definition according to profiles oflym-
phokine activities and secreted proteins . J Immunol. 136:2348.
13 . Mosmann, T. R., T. Yokota, R . Kastelein, S . M. Zurawski, N. Arai, and Y. Takabe .
126
	
ANTI-INTERLEUKIN 4 THERAPY OF MURINE LEISHMANIASIS
1987 . Species-specificity of T cell stimulating activities of IL-2 and BSFl (IL-4) : com-
parison of normal and recombinant, mouse and human IL-2 and BSFl (IL-4) . J. Im-
munol. 138:1813 .
14 . Sadick, M. D ., R . M. Locksley, C . Tubbs, and H . V.'Raff. 1986 . Murine cutaneous leish-
maniasis : resistance correlates with the capacity to generate interferon-'Y in response to
leishmania antigens in vitro. J. Immunol. 136:655 .
15 . Sadick, M . D., and H . V. Raff. 1985 . Leishmania tropica : differences in the antigenicity
of promastigotes and amastigotes . Cell. Immunol. 91:404 .
16 . Dialynas, D. P., Z . S . Quan, K. A . Wall, A . Pierres, J . Quintans, M. R. Loken, M.
Pierres, and F. W. Fitch . 1983 . Characterizatio n ofthe murine T cell surface molecule,
designated L3T4, identified by monoclonal antibody GK1.5 : similarity to the human
Leu-3/T4 molecule . J. Immunol. 131:2445 .
17 . Ledbetter, J . A ., and L . A . Herzenberg . 1979 . Xenogeneic monoclonal antibodies to
mouse lymphoid differentiation antigens . Immunol. Rev. 47:63 .
18 . Spitalny, G . L ., and E . A . Havell . 1984 . Monoclonal antibody to murine gamma inter-
feron inhibits lymphokine-induced antiviral and macrophage turnoricidal activities . J.
Exp. Med. 159:1560 .
19 . Ohara, J ., and W. E . Paul . 1985 . Production of a monoclonal antibody to and molecular
characterization of B-cell stimulatory factor-1 . Nature (Lond). 315:333 .
20 . Lowry, O. H., N . J . Rosebrough, A . L . Farr, and R. J . Randall. 1951 . Protein measure-
ment with the Folin phenol reagent . J. Biol. Chem . 193:265 .
21 . Sacks, D. L., and P. V. Perkins . 1984 . Identification of an infective stage of Leishmania
promastigotes. Science (Wash . DC). 223 :1417 .
22 . Scott, P, P. Natovitz, R. L . Coffman, E . Pearce, and A . Sher. 1988 . Immunoregulation
of cutaneous leishmaniasis . T cell lines that transfer protective immunity or exacerba-
tion belong to different T helper subsets and respond to distinct antigens . J. Exp. Med.
168:1675 .
23 . Chirgwin, J . M., A . E . Przybyla, R . J . MacDonald, and W. J . Rutter. 1979 . Isolatio n
ofbiologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry.
18:5294 .
24 . Aviv, H., and P Leder. 1972 . Purification of biologically active globin messenger RNA
by chromotography on oligothymidylic acid-cellulose . Proc . Natl. Acad. Sci . USA . 69:1408 .
25 . Maniatis, T, E . F. Fitsch, and J . Sambrook. 1982 . Molecular Cloning: A Laboratory
Manual . Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
26 . Meinkoth, J ., and G. Wahl. 1984 . Hybridization of nucleic acids immobilized on solid
supports . Anal. Biochem. 138:267 .
27 . Coffman, R. L ., andJ . Carty. 1986 . A T cell activity that enhances polyclonal IgE produc-
tion and its inhibition by interferon-y . J. Immunol. 136:949 .
28 . McCabe, R. E ., B.J . Luft, andJ . S. Remington . 1984. Effec t of murine interferon gamma
on murine toxoplasmosis . J. Infect. Dis . 150:960 .
29 . Murray, H. W., G . L . Spitalny, and C. F. Nathan . 1985 . Activation ofmouse peritoneal
macrophages in vitro and in vivo by interferon-. y . f Immunol. 134:1619 .
30 . Reed, S . G . 1988 . In vivo administration of recombinant IFN-y induces macrophage
activation, and prevents acute disease, immune suppression, and death in experimental
Trypanosoma cruzi infections . J. Immunol. 140:4342 .
31 . Mitchell, G. F. 1983 . Murine cutaneous leishmaniasis : resistance in reconstituted nude
mice and several F, hybrids infected with Leishmania tropica major. J. Immunogenet. (Oxf.).
10 :395 .
32 . Stevens, T. L ., A . Bossie, V. M. Sanders, R . Fernandez-Botran, R. L . Coffman, T. R .
Mosmann, and E . S . Vitetta . 1988 . Regulation of antibody isotype secretion by subsets
of antigen-specific helper T cells . Nature (Loud.). 334:255 .
SADICK ET AL .
	
127
33 . Finkelman, F. D., I . M . Katona, J. F. Urban, C. M. Snapper, J . H . Ohara, and W. E.
Paul . 1986 . Suppression of in vivo polyclonal IgE responses by monoclonal antibody to
the lymphokine B-cell stimulatory factor 1 . Proc . Nail. Acad. Sci. USA . 83:9675 .
34 . Snapper, C . M., F. D. Finkelman, D. Stefany, D. H . Conrad, and W. E . Paul . 1988 . IL-4
induces co-expression of intrinsic membrane IgG1 and IgE by murine B cells stimulated
with lipopolysaccharide . J. Immunol. 141:489 .
35 . Cherwinski, H. M., J . H . Schumacher, K. D. Brown, and T. R. Mosmann. 1987 . Two
types of mouse helper T cell clone . III . Further differences in lymphokine synthesis be-
tween Thl and Th2 clones revealed by RNA hybridization, functionally monospecific
bioassays, and monoclonal antibodies . J. Exp. Med. 166:1229.
36 . Gajewski, T. F., and F. W. Fitch. 1988 . Anti-proliferatioe effect ofIFN-y in immune regu-
lation . I . IFN-y inhibits the proliferation ofTh2 but not Thl murine helper T lympho-
cyte clones . J Immunol. 140:4245 .
37 . Essner, R., K . Rhoades, W. H . McBride, D. L . Morton, and J . S . Economou . 1989.
IL-4 down-regulates IL-1 and TNF gene expression in human monocytes . J. Immunol.
142:3857 .
38 . Lehn, M., S . Englehorn, H. G. Remold, and W Y. Weiser. 1989 . IL-4 abrogates the
activation of human cultured monocytes by IFN-y . FASEB (Fed. Am. Soc. Exp. BioL) J.
3 :A822 .
39 . Nacy, C . A., M. S . Meltzer, E. J . Leonard, and D. J . Wyler. 1981 . Intracellula r replica-
tion and lymphokine-induced destruction ofLeishmania tropica in C3H/HeN mouse mac-
rophages . J. Immunol. 127 :2381 .
40 . Belosevic, M., D. S. Finbloom, P. H . Van Der Meide, M. Slayter, and C . A . Nacy. 1989.
Administratio n ofmonoclonal anti-IFN-y antibodies in vivo abrogates natural resistance
of C3H/HeN mice to infection with Leishmania major. J Immunol. 143:266 .
41 . Farrell, J . P., I . Muller, and J . A . Louis . 1989 . A role for Lyt-2* T cells in resistance
to cutaneous leishmaniasis in immunized mice. J. Immunol. 142:2052 .
42 . Hill, J . O., M. Awwad, and R. J . North . 1989 . Elimination of CD4' suppressor T cells
from susceptible BALB/c mice releases CD8' T lymphocytes to mediate protective im-
munity against Leishmania . J Exp. Med. 169:1819 .
43 . Belosevic, M., C . E . Davis, M. S. Meltzer, and C . A . Nacy. 1988 . Regulation of activated
macrophage antimicrobial activities . Identification of lymphokines that cooperate with
IFN-y for induction of resistance to infection . J. Immunol. 141:890 .
44 . Davis, C . E., M. Belosevic, M. S. Meltzer, and C . A . Nacy. 1988 . Regulation of activated
macrophage antimicrobial activities . Cooperation of lymphokines for induction ofresis-
tance to infection . J Immunol. 141 :627 .
45 . Sypek, J . P., C . B . Panosian, and D. J . Wyler. 1984 . Cell contact-mediated macrophage
activation for antileishmanial defense . II . Identification of effector cell phenotype and
genetic restriction . J Immunol. 133:3351 .
46 . Panosian, C., J . Sypek, and D. Wyler. 1984 . Cell contact-mediated macrophage activa-
tion for antileishmanial defense . I . Lymphocyte effector mechanism that is contact de-
pendent and noncytotoxic . J Immunol. 133:3358 .
